Clients

Oramed Pharmaceuticals Inc.

Company Snapshot: Oramed Pharmaceuticals Inc.

ORMP
Last Change Volume High Low

Company Overview

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

Client News

  1. Feb 4 2020 Oramed to Present at BIO CEO & Investor Conference
  2. Jan 30 2020 Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
  3. Jan 28 2020 Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
  4. Jan 23 2020 Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
  5. Jan 21 2020 Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board